Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) ended Wednesday session in green amid volatile trading. The shares closed up +0.49 points or 3.59% at $14.13 with 343,891.00 shares getting traded. Post opening the session at $13.80, the shares hit an intraday low of $13.69 and an intraday high of $14.33 and the price vacillated in this range throughout the day. The company has a market cap of $314.49 million and the numbers of outstanding shares have been calculated to be 22.55 million shares.
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Its lead product candidate is ETC-1002 or Bempedoic acid, an inhibitor of ATP Citrate Lyase, an enzyme on the cholesterol biosynthesis pathway that is in Phase III long-term safety and tolerability study to treat patients with hypercholesterolemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol, and up-regulates LDL-receptors, resulting in increased LDL-C clearance and reduced plasma levels of LDL-C. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Wednesday session in green amid volatile trading. The shares closed up +0.68 points or 5.47% at $13.12 with 6.96 million shares getting traded. Post opening the session at $12.37, the shares hit an intraday low of $12.21 and an intraday high of $13.17 and the price vacillated in this range throughout the day. The company has a market cap of $2.96 billion and the numbers of outstanding shares have been calculated to be 230.33 million shares.
Exelixis, Inc. (EXEL) announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company’s Board of Directors. Ms. Smith’s appointment took effect on September 22, 2016.
Ms. Smith has nearly two decades of operational leadership experience in high growth public, private, startup, and established biopharmaceutical businesses. She currently serves as president and chief executive officer of Raptor Pharmaceuticals, a commercial-stage, global innovator in the development and commercialization of orphan disease therapies. Ms. Smith previously held key commercial and strategic leadership positions at companies including Enobia Pharma, Jazz Pharmaceuticals, and Genzyme.
“I’m delighted to welcome Julie Anne Smith to the Exelixis board of directors,” said Stelios Papadopoulos, Ph.D., an Exelixis-co-founder and chairman of the company’s board. “Her deep commercial expertise will serve Exelixis well as the company continues to execute on the launch of its latest therapy, CABOMETYX, following regulatory approval in the United States earlier this year.”